Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
10.66
Dollar change
-0.05
Percentage change
-0.47
%
Index- P/E- EPS (ttm)-0.68 Insider Own43.70% Shs Outstand52.03M Perf Week0.66%
Market Cap554.64M Forward P/E- EPS next Y-1.26 Insider Trans0.00% Shs Float29.29M Perf Month29.53%
Income-35.59M PEG- EPS next Q-0.22 Inst Own56.32% Short Float4.48% Perf Quarter93.82%
Sales0.00M P/S- EPS this Y-37.94% Inst Trans-2.83% Short Ratio9.21 Perf Half Y6.18%
Book/sh4.21 P/B2.53 EPS next Y-34.75% ROA-14.81% Short Interest1.31M Perf Year42.32%
Cash/sh3.11 P/C3.43 EPS next 5Y- ROE-15.18% 52W Range5.05 - 14.64 Perf YTD83.79%
Dividend Est.- P/FCF- EPS past 5Y-253.12% ROI-16.21% 52W High-27.19% Beta0.84
Dividend TTM- Quick Ratio24.49 Sales past 5Y0.00% Gross Margin- 52W Low111.09% ATR (14)0.79
Dividend Ex-Date- Current Ratio24.49 EPS Y/Y TTM-58.32% Oper. Margin0.00% RSI (14)63.09 Volatility5.53% 9.99%
Employees49 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price31.75
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q32.03% Payout- Rel Volume0.31 Prev Close10.71
Sales Surprise- EPS Surprise-4.90% Sales Q/Q- EarningsFeb 29 BMO Avg Volume142.47K Price10.66
SMA209.81% SMA5027.70% SMA20017.33% Trades Volume44,423 Change-0.47%
Date Action Analyst Rating Change Price Target Change
Aug-16-22Initiated H.C. Wainwright Buy $45
Jun-16-22Initiated ROTH Capital Buy $66
Mar-05-24 09:55AM
Feb-29-24 07:00AM
Jan-18-24 04:30PM
Jan-16-24 09:55AM
Dec-29-23 08:47AM
02:15PM Loading…
Dec-20-23 02:15PM
Dec-19-23 11:07AM
Nov-09-23 04:45PM
Sep-29-23 04:45PM
Aug-23-23 07:00AM
Jul-17-23 11:53AM
Jul-06-23 09:40AM
Jun-29-23 08:00AM
May-11-23 07:30AM
Mar-23-23 01:56PM
12:22PM Loading…
Mar-12-23 12:22PM
Mar-02-23 07:00AM
Feb-07-23 10:15AM
Jan-09-23 07:30AM
Nov-21-22 12:22PM
Nov-10-22 07:05AM
Sep-14-22 09:55AM
Aug-30-22 03:02PM
Aug-29-22 09:55AM
Aug-23-22 07:00AM
May-18-22 07:00AM
Mar-28-22 07:04AM
Mar-24-22 11:48AM
Dec-06-21 07:10AM
07:00AM
04:50AM Loading…
Oct-27-21 04:50AM
Sep-25-21 10:07AM
Sep-23-21 05:25PM
Jul-02-21 04:20PM
Jun-25-21 01:23PM
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schonharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.